Skip to main content

Expert opinion

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Concise and thought-provoking commentary, opinion and analysis from leading rheumatology experts.

Methotrexate versus etanercept as first-line therapy for psoriatic arthritis

Syringe and white pills on blue background

William Tillett, Deepak Jadon, and Jobie Evans debate the clinical reasons relating to the efficacy, safety, and practicality of using etanercept or methotrexate as first-line therapy for psoriatic arthritis.

20-06-2019 | Systemic lupus erythematosus | Highlight | Article

Systemic lupus erythematosus: Novel therapies and targeted treatments

Andrea Fava and George Stojan review new strategies and agents for the treatment of systemic lupus erythematosus that have most recently showed promise in clinical trials.

12-04-2019 | Gout | Editorial | Article

Using genetic studies to assess the impact of hyperuricemia in cardiometabolic and chronic kidney disease

Editorial Board member Fernando Pérez-Ruiz discusses the impact of hyperuricemia in cardiometabolic and chronic kidney disease, focusing on the role of genetic studies in showing a causal association between these conditions.

27-03-2019 | Juvenile idiopathic arthritis | Editorial | Article

Temporomandibular joint involvement in juvenile idiopathic arthritis: Diagnosis and management

The authors provide an overview of temporomandibular joint involvement in children with juvenile idiopathic arthritis, including imaging methods for diagnosis, clinical examination recommendations, and treatment options.

18-03-2019 | Juvenile idiopathic arthritis | Editorial | Article

Enhancing clinical assessment with ultrasonography in juvenile idiopathic arthritis

Johannes Roth outlines the rationale behind the use of musculoskeletal ultrasonography in children with juvenile idiopathic arthritis, including enhancement of clinical assessment as part of a treat-to-target approach.

01-03-2019 | Juvenile idiopathic arthritis | Editorial | Article

The microbiota in juvenile idiopathic arthritis: What’s wrong, and what can we do?

In this editorial, Matthew Stoll explores the role of the microbiota in the pathogenesis of juvenile idiopathic arthritis, as well as current research into therapeutic alterations of the microbiome.

18-02-2019 | Osteoporosis | Editorial | Article

Osteoporosis therapy: Drug holiday or not?

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

12-02-2019 | Cardiovascular disease | Editorial | Article

Cardiovascular risk management in arthritis: Why still a bridge too far?

Cardiovascular disease is the main cause of death in patients with rheumatoid arthritis. In this editorial Michael Nurmohamed discusses the EULAR recommendations for cardiovascular risk management, focusing on the role of the rheumatologist.

11-02-2019 | Rheumatoid arthritis | Editorial | Article

20 years of TNF inhibitors in rheumatoid arthritis

Understanding and treatment of rheumatoid arthritis has changed dramatically over the past two decades. Peter Taylor describes the impact of biologic tumor necrosis factor inhibitors on the management of this disease.

29-01-2019 | Lupus nephritis | Editorial | Article

Emerging therapies for lupus nephritis

Lupus nephritis is the most common organ-threatening complication of systemic lupus erythematosus, and current treatment regimens are only partially effective and are potentially toxic. In this editorial, the authors focus on emerging therapeutics to treat this disease.

11-01-2019 | Psoriatic arthritis | Editorial | Article

Screening psoriasis patients for development of psoriatic arthritis

Vinod Chandran discusses recent developments in screening tools for identifying patients with psoriatic arthritis, and those who are at high risk for developing this disease.

Image Credits